Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. / Koshino, Akihiko; Schechter, Meir; Chertow, Glenn M; Vart, Priya; Jongs, Niels; Toto, Robert D; Rossing, Peter; Correa-Rotter, Ricardo; McMurray, John J V; Górriz, Jose Luis; Isidto, Rey; Kashihara, Naoki; Langkilde, Anna Maria; Wheeler, David C; Heerspink, Hiddo J L.

I: NEJM Evidence, Bind 2, Nr. 6, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Koshino, A, Schechter, M, Chertow, GM, Vart, P, Jongs, N, Toto, RD, Rossing, P, Correa-Rotter, R, McMurray, JJV, Górriz, JL, Isidto, R, Kashihara, N, Langkilde, AM, Wheeler, DC & Heerspink, HJL 2023, 'Dapagliflozin and Anemia in Patients with Chronic Kidney Disease', NEJM Evidence, bind 2, nr. 6. https://doi.org/10.1056/EVIDoa2300049

APA

Koshino, A., Schechter, M., Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Rossing, P., Correa-Rotter, R., McMurray, J. J. V., Górriz, J. L., Isidto, R., Kashihara, N., Langkilde, A. M., Wheeler, D. C., & Heerspink, H. J. L. (2023). Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM Evidence, 2(6). https://doi.org/10.1056/EVIDoa2300049

Vancouver

Koshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD o.a. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM Evidence. 2023;2(6). https://doi.org/10.1056/EVIDoa2300049

Author

Koshino, Akihiko ; Schechter, Meir ; Chertow, Glenn M ; Vart, Priya ; Jongs, Niels ; Toto, Robert D ; Rossing, Peter ; Correa-Rotter, Ricardo ; McMurray, John J V ; Górriz, Jose Luis ; Isidto, Rey ; Kashihara, Naoki ; Langkilde, Anna Maria ; Wheeler, David C ; Heerspink, Hiddo J L. / Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. I: NEJM Evidence. 2023 ; Bind 2, Nr. 6.

Bibtex

@article{b9acb3b3607142329b62d2747a54aa5a,
title = "Dapagliflozin and Anemia in Patients with Chronic Kidney Disease",
abstract = "DAPA and Anemia in Patients with CKDThis post hoc analysis of the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of dapagliflozin treatment on the correction and prevention of anemia. Results over a 2.4-year median follow-up show that dapagliflozin is associated with increase in hematocrit, correction of anemia, and reduced risk of incident anemia in patients with CKD with or without type 2 diabetes.",
keywords = "Humans, Anemia, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Renal Insufficiency, Chronic",
author = "Akihiko Koshino and Meir Schechter and Chertow, {Glenn M} and Priya Vart and Niels Jongs and Toto, {Robert D} and Peter Rossing and Ricardo Correa-Rotter and McMurray, {John J V} and G{\'o}rriz, {Jose Luis} and Rey Isidto and Naoki Kashihara and Langkilde, {Anna Maria} and Wheeler, {David C} and Heerspink, {Hiddo J L}",
year = "2023",
doi = "10.1056/EVIDoa2300049",
language = "English",
volume = "2",
journal = "NEJM Evidence",
issn = "2766-5526",
publisher = "Massachussetts Medical Society",
number = "6",

}

RIS

TY - JOUR

T1 - Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

AU - Koshino, Akihiko

AU - Schechter, Meir

AU - Chertow, Glenn M

AU - Vart, Priya

AU - Jongs, Niels

AU - Toto, Robert D

AU - Rossing, Peter

AU - Correa-Rotter, Ricardo

AU - McMurray, John J V

AU - Górriz, Jose Luis

AU - Isidto, Rey

AU - Kashihara, Naoki

AU - Langkilde, Anna Maria

AU - Wheeler, David C

AU - Heerspink, Hiddo J L

PY - 2023

Y1 - 2023

N2 - DAPA and Anemia in Patients with CKDThis post hoc analysis of the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of dapagliflozin treatment on the correction and prevention of anemia. Results over a 2.4-year median follow-up show that dapagliflozin is associated with increase in hematocrit, correction of anemia, and reduced risk of incident anemia in patients with CKD with or without type 2 diabetes.

AB - DAPA and Anemia in Patients with CKDThis post hoc analysis of the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of dapagliflozin treatment on the correction and prevention of anemia. Results over a 2.4-year median follow-up show that dapagliflozin is associated with increase in hematocrit, correction of anemia, and reduced risk of incident anemia in patients with CKD with or without type 2 diabetes.

KW - Humans

KW - Anemia

KW - Benzhydryl Compounds

KW - Diabetes Mellitus, Type 2

KW - Glucosides

KW - Renal Insufficiency, Chronic

U2 - 10.1056/EVIDoa2300049

DO - 10.1056/EVIDoa2300049

M3 - Journal article

C2 - 38320128

VL - 2

JO - NEJM Evidence

JF - NEJM Evidence

SN - 2766-5526

IS - 6

ER -

ID: 385016525